Operator Hi, good morning, guys, and congratulations on a great quarter. I just want to focus in, if I could, on the resupply program, you said in the press release it's 169,000 patients now in the program. Can you give us an idea of what the average reorder rate is per patient for the year and what the average revenue per reorder is? Greg Crawford Doug Cooper Greg Crawford Doug Cooper Yes, that's it. That's about right. Yes. Greg Crawford This is predominantly hoses and masks, I'm guessing, right? So it wo ...

Company Participants Thank you for standing by. This is the conference operator. Welcome to the Fiscal Third Quarter 2023 Earnings Results Conference Call for Quipt Home Medical Corp. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation there will be opportunity for analytics to ask questions. [Operator Instructions]. At this point, I'd like to turn the conference over to Mr. Chairman and Chief Executive Officer, Greg Crawford. Please go ahead. ...

Table of Contents Exhibit 99.1 Quipt Home Medical Corp. Condensed Consolidated Interim Financial Statements 2023 Third Quarter For the three and nine months ended June 30, 2023 and 2022 (UNAUDITED) (Expressed in thousands of US Dollars, except per share amounts) | | | As at | | As at | | --- | --- | --- | --- | --- | | | | June 30, 2023 | | September 30, 2022 | | ASSETS | | | | | | Current Assets | | | | | | Cash | $ | 20,445 | $ | 8,516 | | Accounts receivable, net | | 23,817 | | 16,383 | | Inventory | | 1 ...

This concludes today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day. Yeah. We think there's probably about another 12 to 15 states in that that would kind of fit the bill there for us that have a high prevalence in that of cardio and pulmonary disease states, especially COPD that we'd like to get into. Julian Hung All right. Thank you so much for taking the question today. Greg Crawford Thank you. Operator This concludes the question-and-answer session ...

Part I [Condensed Consolidated Interim Statements of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Financial%20Position) Quipt's total assets grew to **$225.5 million**, driven by acquisitions, while liabilities surged to **$143.7 million** due to increased debt Consolidated Balance Sheet Summary (in thousands of US Dollars) | Account | March 31, 2023 | September 30, 2022 | Change | | :--- | :--- | :--- | :--- | | **Total Current Assets** | $49,492 | $41,536 | +19.2% | | **Total Long-term Assets** | $176,051 | $90,678 | +94.1% | | **TOTAL ASSETS** | **$225,543** | **$132,214** | **+70.6%** | | **Total Current Liabilities** | $68,170 | $41,740 | +63.3% | | **Total Long-term Liabilities** | $75,571 | $10,927 | +591.6% | | **TOTAL LIABILITIES** | **$143,741** | **$52,667** | **+172.9%** | | **TOTAL SHAREHOLDERS' EQUITY** | **$81,802** | **$79,547** | **+2.8%** | - The significant increase in long-term assets is mainly attributable to a rise in Goodwill (from **$28.2 million** to **$50.7 million**) and Intangible Assets (from **$28.9 million** to **$73.0 million**), reflecting the impact of recent business acquisitions[4](index=4&type=chunk) - The sharp rise in long-term liabilities was primarily caused by increased drawings on the senior credit facility, which grew from **$3.4 million** to **$63.0 million** to finance acquisitions[4](index=4&type=chunk) [Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss)](index=4&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Income%20(Loss)%20and%20Comprehensive%20Income%20(Loss)) Revenue grew **73.2%** to **$58.1 million**, but a net loss of **$0.7 million** resulted from higher expenses and no grant income Income Statement Summary (in thousands of US Dollars) | Metric | Three Months Ended Mar 31, 2023 | Three Months Ended Mar 31, 2022 | Six Months Ended Mar 31, 2023 | Six Months Ended Mar 31, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenues** | $58,120 | $33,553 | $98,935 | $63,077 | | **Operating Income** | $1,311 | $4,444 | $2,684 | $3,262 | | **Net Income (Loss)** | $(749) | $5,036 | $(425) | $2,905 | | **Basic EPS** | $(0.02) | $0.15 | $(0.01) | $0.09 | | **Diluted EPS** | $(0.02) | $0.14 | $(0.01) | $0.08 | - Revenue from sales of medical equipment and supplies grew more rapidly (**114.2%** YoY for the three months) than rentals of medical equipment (**37.2%** YoY)[6](index=6&type=chunk) - The prior year's results for the three and six months ended March 31, 2022, included a one-time income of **$4.25 million** from a government grant, which significantly impacts the year-over-year comparison of net income[6](index=6&type=chunk) [Condensed Consolidated Interim Statements of Changes in Shareholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Changes%20in%20Shareholders'%20Equity) Shareholders' equity increased to **$81.8 million**, driven by stock issuance for acquisitions and compensation, despite a net loss Reconciliation of Shareholders' Equity (in thousands of US Dollars) | Description | Amount | | :--- | :--- | | **Balance at September 30, 2022** | **$79,547** | | Net loss | $(425) | | Stock issued for Great Elm acquisition | $2,060 | | Settlement of restricted stock units | $(1,338) | | Exercise of options | $81 | | Stock-based compensation | $1,877 | | **Balance at March 31, 2023** | **$81,802** | [Condensed Consolidated Interim Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Cash%20Flows) Operating cash flow rose to **$14.8 million**, but acquisitions led to a **$77.6 million** outflow, funded by **$56.4 million** in new debt Summary of Cash Flows (in thousands of US Dollars) | Cash Flow Activity | Six months ended March 31, 2023 | Six months ended March 31, 2022 | | :--- | :--- | :--- | | **Net cash flow from operating activities** | $14,816 | $11,821 | | **Net cash flow used in investing activities** | $(77,600) | $(19,941) | | **Net cash flow from financing activities** | $56,366 | $(9,021) | | **Net decrease in cash** | $(6,418) | $(17,141) | | **Cash, beginning of period** | $8,516 | $34,612 | | **Cash, end of period** | $2,087 | $17,394 | - The primary use of cash in investing activities was **$72.7 million** paid for acquisitions, a substantial increase from **$16.5 million** in the prior-year period[11](index=11&type=chunk) - Financing activities were dominated by the issuance of **$70.0 million** in debt under a new senior credit facility, which was used to fund acquisitions[11](index=11&type=chunk) Notes to the Condensed Consolidated Interim Financial Statements [Note 1: Nature of Operations](index=9&type=section&id=1.%20Nature%20of%20operations) Quipt Home Medical Corp. provides durable medical respiratory equipment and services as a Medicare provider - The company's core business is providing a range of home medical respiratory equipment and services as a participating Medicare provider[12](index=12&type=chunk) [Note 3: Business Acquisitions](index=9&type=section&id=3.%20Business%20acquisitions) Quipt acquired Great Elm Healthcare for **$74.7 million**, primarily cash, significantly boosting assets - On January 3, 2023, Quipt acquired Great Elm Healthcare, LLC for a purchase price of **$74,749,000**, comprised of approximately **$72,689,000** in cash and 431,996 Quipt common shares valued at **$2,060,000**[16](index=16&type=chunk) Provisional Fair Value of Net Assets Acquired from Great Elm (in thousands of US Dollars) | Account | Fair Value | | :--- | :--- | | Goodwill | $23,061 | | Intangible assets | $46,410 | | Property, equipment, and right of use assets | $15,199 | | Other Net Assets / (Liabilities) | $(9,821) | | **Net assets acquired** | **$74,749** | [Note 7: Goodwill and Intangible Assets](index=11&type=section&id=7.%20Goodwill%20and%20Intangible%20Assets) Goodwill increased to **$50.7 million** and intangible assets to **$73.0 million**, primarily due to recent acquisitions Changes in Goodwill and Intangible Assets (in thousands of US Dollars) | Account | Balance Sep 30, 2022 | Additions from Acquisitions | Balance Mar 31, 2023 | | :--- | :--- | :--- | :--- | | Goodwill | $28,208 | $23,061 | $50,725 | | Net Intangible Assets | $28,887 | $46,410 | $73,042 | [Note 8: Government Grant](index=12&type=section&id=8.%20Government%20Grant) Prior year's **$4.254 million** PPP loan forgiveness significantly impacts current period profitability comparisons - A **$4,254,000** PPP loan was forgiven on March 23, 2022, and recorded as income in the prior-year period. The absence of this one-time gain in the current period is a key factor in the decline in net income[29](index=29&type=chunk) [Note 10: Long-term Debt](index=14&type=section&id=10.%20Long-term%20Debt) New **$110 million** senior credit facility has **$81.1 million** outstanding, primarily funding the Great Elm acquisition - The company entered a new **$110 million** senior credit facility, consisting of an **$85 million** delayed draw term loan, a **$5 million** term loan, and a **$20 million** revolving credit facility[31](index=31&type=chunk) - As of March 31, 2023, the total outstanding balance under the new facility was **$81,075,000**. The cash from this facility was used to partially fund the acquisition of Great Elm[31](index=31&type=chunk)[32](index=32&type=chunk) - The company paid off its SBA Loan during the quarter, resulting in a loss on extinguishment of approximately **$30,000**[44](index=44&type=chunk) [Note 11: Share Capital](index=18&type=section&id=11.%20Share%20capital) Share capital activities involved issuing **435,000** options and **831,000** RSUs, with **526,193** shares issued for settlements Stock Option Activity (in thousands) | Description | Number of options | Weighted avg. exercise price (C$) | | :--- | :--- | :--- | | **Balance Sep 30, 2022** | **3,751** | **4.24** | | Issued | 435 | 8.30 | | Exercised | (50) | 2.20 | | Expired/Forfeited | (82) | - | | **Balance Mar 31, 2023** | **4,054** | **4.54** | - On February 20, 2023, **831,000** restricted stock units were granted to officers and directors, vesting over two years[53](index=53&type=chunk) - Stock-based compensation expense for the six months ended March 31, 2023, was **$1.9 million**, down from **$3.3 million** in the prior-year period[56](index=56&type=chunk) [Note 13: Operating Expenses](index=21&type=section&id=13.%20Operating%20expenses) Operating expenses rose **58.9%** to **$47.1 million**, driven by a **66.6%** increase in payroll and benefits from acquisitions Operating Expenses Breakdown (in thousands of US Dollars) | Expense Category | Six months ended Mar 31, 2023 | Six months ended Mar 31, 2022 | YoY Change | | :--- | :--- | :--- | :--- | | Payroll and employee benefits | $30,955 | $18,583 | +66.6% | | Billing | $4,201 | $2,846 | +47.6% | | All other | $11,992 | $8,241 | +45.5% | | **Total operating expenses** | **$47,148** | **$29,670** | **+58.9%** | [Note 17: Subsequent Event](index=23&type=section&id=17.%20Subsequent%20event) April 25, 2023 public offering raised **$28.9 million** net proceeds, used to repay the revolving credit facility - The company raised approximately **$28.9 million** in net proceeds from a share offering on April 25, 2023[66](index=66&type=chunk) - A portion of the proceeds was used to fully repay the outstanding balance on the revolving credit facility[66](index=66&type=chunk)

Quipt Home Medical Corp. (NASDAQ:QIPT) Q1 2023 Earnings Conference Call February 14, 2023 10:01 AM ET Greg Crawford – Chairman and Chief Executive Officer Hardik Mehta – Chief Financial Officer We remind you that the remarks today will include forward-looking statements that are subject to important risks and uncertainties. For more information on these risks and uncertainties, please see the reader advisory at the bottom of the company's results news release. The company's actual performance could differ m ...

[Condensed Consolidated Interim Financial Statements](index=1&type=section&id=Condensed%20Consolidated%20Interim%20Financial%20Statements) This section presents the unaudited condensed consolidated interim financial statements, including the statements of financial position, income, changes in equity, and cash flows, along with their explanatory notes [Condensed Consolidated Interim Statements of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Financial%20Position) As of December 31, 2022, total assets were **$131.7 million** and total liabilities were **$51.3 million**, with shareholders' equity at **$80.4 million**, reflecting slight shifts from September 30, 2022 Consolidated Balance Sheet (As of Dec 31, 2022 vs. Sep 30, 2022) | Account | Dec 31, 2022 ($ thousands) | Sep 30, 2022 ($ thousands) | | :--- | :--- | :--- | | **Total Current Assets** | 38,955 | 41,536 | | **Total Long-term Assets** | 92,770 | 90,678 | | **TOTAL ASSETS** | **131,725** | **132,214** | | **Total Current Liabilities** | 37,100 | 41,740 | | **Total Long-term Liabilities** | 14,182 | 10,927 | | **TOTAL LIABILITIES** | **51,282** | **52,667** | | **TOTAL SHAREHOLDERS' EQUITY** | **80,443** | **79,547** | | **TOTAL LIABILITIES AND EQUITY** | **131,725** | **132,214** | [Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss)](index=4&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Income%20%28Loss%29%20and%20Comprehensive%20Income%20%28Loss%29) For the three months ended December 31, 2022, the company achieved a net income of **$325,000** and **38.2%** revenue growth to **$40.8 million**, a significant turnaround from a net loss in the prior year Income Statement Highlights (Three Months Ended Dec 31) | Metric | 2022 ($ thousands) | 2021 ($ thousands) | Change | | :--- | :--- | :--- | :--- | | Total Revenues | 40,815 | 29,525 | +38.2% | | Operating Income (Loss) | 1,374 | (1,180) | Turnaround to Profit | | Net Income (Loss) | 325 | (2,131) | Turnaround to Profit | | Basic EPS | $0.01 | $(0.06) | +$0.07 | | Diluted EPS | $0.01 | $(0.06) | +$0.07 | [Condensed Consolidated Interim Statements of Changes in Shareholders' Equity](index=5&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Changes%20in%20Shareholders%27%20Equity) Shareholders' equity increased from **$79.5 million** to **$80.4 million** during the quarter, primarily due to **$325,000** in net income and **$571,000** in stock-based compensation Changes in Shareholders' Equity (Three Months Ended Dec 31, 2022) | Description | Amount ($ thousands) | | :--- | :--- | | Balance at Sep 30, 2022 | 79,547 | | Net Income | 325 | | Stock-based compensation | 571 | | **Balance at Dec 31, 2022** | **80,443** | [Condensed Consolidated Interim Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Cash%20Flows) For the three months ended December 31, 2022, operating activities provided **$4.8 million** in cash, while investing and financing activities used **$1.3 million** and **$8.4 million** respectively, leading to a net cash decrease of **$4.9 million** Cash Flow Summary (Three Months Ended Dec 31, 2022) | Activity | Amount ($ thousands) | | :--- | :--- | | Net cash flow from operating activities | 4,832 | | Net cash flow used in investing activities | (1,301) | | Net cash flow used in financing activities | (8,388) | | **Net decrease in cash** | **(4,857)** | | Cash, beginning of period | 8,516 | | **Cash, end of period** | **3,656** | [Notes to the Condensed Consolidated Interim Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Interim%20Financial%20Statements) This section provides detailed explanations of accounting policies and financial figures, covering business operations, acquisition strategy, asset and liability breakdowns, share capital, and significant subsequent events [Note 1: Nature of operations](index=8&type=section&id=Note%201%3A%20Nature%20of%20operations) This note describes the company's primary business as a Medicare provider of durable medical respiratory equipment and its active acquisition strategy - The company is a Medicare provider of durable medical respiratory equipment and services, including nebulizers, oxygen concentrators, CPAP/BiPAP units, and non-invasive ventilation equipment[11](index=11&type=chunk) - Quipt has an active acquisition strategy to drive revenue and profit growth[11](index=11&type=chunk) [Note 2: Summary of significant accounting policies](index=8&type=section&id=Note%202%3A%20Summary%20of%20significant%20accounting%20policies) This note outlines the significant accounting policies used in preparing the unaudited condensed consolidated interim financial statements, consistent with IFRS - The unaudited condensed consolidated interim financial statements are prepared in accordance with International Accounting Standard (IAS) 34, 'Interim Financial Reporting', and are consistent with IFRS[13](index=13&type=chunk) [Note 3: Purchase Price Payable](index=9&type=section&id=Note%203%3A%20Purchase%20Price%20Payable) This note details the decrease in purchase price payable related to prior acquisitions, following payments made during the period - The purchase price payable, related to prior acquisitions, decreased from **$5.8 million** at September 30, 2022, to **$5.0 million** at December 31, 2022, after payments of **$823,000**[15](index=15&type=chunk) [Note 4: Accounts Receivable](index=9&type=section&id=Note%204%3A%20Accounts%20Receivable) This note provides a breakdown of accounts receivable, including gross amounts and reserves for expected credit losses, and highlights the portion due from Medicare Accounts Receivable Breakdown ($ thousands) | Category | Dec 31, 2022 | Sep 30, 2022 | | :--- | :--- | :--- | | Gross receivable | 27,788 | 27,122 | | Reserve for expected credit losses | (10,610) | (10,739) | | **Total** | **17,178** | **16,383** | - As of December 31, 2022, approximately **9%** of the company's receivables were due from Medicare[16](index=16&type=chunk) [Note 5: Inventory](index=9&type=section&id=Note%205%3A%20Inventory) This note presents a detailed breakdown of inventory, distinguishing between serialized and non-serialized items and accounting for reserves Inventory Breakdown ($ thousands) | Category | Dec 31, 2022 | Sep 30, 2022 | | :--- | :--- | :--- | | Serialized | 7,132 | 5,814 | | Non-serialized | 9,817 | 9,854 | | Reserve for shrink and slow-moving | (83) | (83) | | **Total Inventory** | **16,866** | **15,585** | [Note 7: Goodwill and Intangible Assets](index=10&type=section&id=Note%207%3A%20Goodwill%20and%20Intangible%20Assets) This note details the net carrying amount of goodwill and intangible assets, including the amortization expense for the period Net Carrying Amount of Goodwill & Intangibles ($ thousands) | Asset | Dec 31, 2022 | Sep 30, 2022 | | :--- | :--- | :--- | | Goodwill | 28,208 | 28,208 | | Intangible Assets, net | 28,086 | 28,887 | | **Total** | **56,294** | **57,095** | - Amortization of intangible assets for the three months ended December 31, 2022, was **$801,000**[21](index=21&type=chunk) [Note 8: Government Grant](index=12&type=section&id=Note%208%3A%20Government%20Grant) This note clarifies the status of government grants, including the full forgiveness of the PPP loan and recognition of the Relief Fund - The **$4.25 million** Payroll Protection Plan (PPP) loan received in 2020 was fully forgiven in March 2022[23](index=23&type=chunk) - The **$1.8 million** from the Public Health and Social Services Emergency Fund (Relief Fund) has been fully recognized, with no remaining liability as of December 31, 2022[24](index=24&type=chunk)[25](index=25&type=chunk) [Note 10: Long-term Debt](index=12&type=section&id=Note%2010%3A%20Long-term%20Debt) This note provides details on the company's long-term debt, including the senior credit facility, equipment loans, lease liabilities, and the status of convertible debentures - In September 2022, the company entered a five-year, **$110 million** senior credit facility, consisting of an **$85 million** delayed draw term loan, a **$5 million** term loan, and a **$20 million** revolving credit facility[27](index=27&type=chunk) - As of December 31, 2022, the outstanding balance under the new facility was **$8.04 million**[28](index=28&type=chunk) - The C**$15 million** in **8.0%** Convertible Unsecured Debentures issued in 2019 were fully converted during the year ended September 30, 2022, with no balance outstanding[32](index=32&type=chunk) Key Debt Balances (as of Dec 31, 2022) | Debt Type | Balance ($ thousands) | | :--- | :--- | | Senior Credit Facility (Net) | 6,332 | | Equipment Loans | 6,559 | | Lease Liabilities | 13,660 | | SBA Loan | 120 | [Note 11: Share capital](index=18&type=section&id=Note%2011%3A%20Share%20capital) This note details the components of share capital, including total shareholders' equity, outstanding stock options, restricted stock units, and stock-based compensation expense - Total shareholders' equity was **$80.4 million** as of December 31, 2022[41](index=41&type=chunk) - As of December 31, 2022, there were **3,689,000** stock options outstanding with a weighted average exercise price of C**$4.09**[48](index=48&type=chunk) - As of December 31, 2022, there were **848,750** restricted stock units (RSUs) from the May 2021 grant and **81,340** from the February 2022 grant outstanding[49](index=49&type=chunk)[50](index=50&type=chunk) - Stock-based compensation expense was **$571,000** for the three months ended December 31, 2022, a significant decrease from **$2,110,000** in the prior-year period[53](index=53&type=chunk) [Note 13: Operating expenses](index=22&type=section&id=Note%2013%3A%20Operating%20expenses) This note provides a detailed breakdown of the company's operating expenses for the three months ended December 31, comparing current and prior-year figures Operating Expenses Breakdown (Three Months Ended Dec 31) | Expense Category | 2022 ($ thousands) | 2021 ($ thousands) | | :--- | :--- | :--- | | Payroll and employee benefits | 12,359 | 8,618 | | Facilities | 1,044 | 600 | | Billing | 1,879 | 1,387 | | Professional fees | 992 | 635 | | All other | 3,188 | 2,174 | | **Total operating expenses** | **19,462** | **13,414** | [Note 15: Income (loss) per share](index=22&type=section&id=Note%2015%3A%20Income%20%28loss%29%20per%20share) This note details the calculation of basic and diluted earnings per share, reflecting the net income or loss and weighted average shares outstanding Earnings Per Share Calculation (Three Months Ended Dec 31) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Net income (loss) ($ thousands) | 325 | (2,131) | | Basic weighted average shares (000's) | 35,605 | 33,346 | | Diluted weighted average shares (000's) | 38,148 | 33,346 | | **Basic EPS** | **$0.01** | **$(0.06)** | | **Diluted EPS** | **$0.01** | **$(0.06)** | [Note 16: Related party transactions](index=22&type=section&id=Note%2016%3A%20Related%20party%20transactions) This note discloses transactions with related parties, including lease agreements with an affiliated rental company and compensation for key management personnel - The company leases six facilities from a rental company affiliated with its CEO, with monthly lease payments of approximately **$65,000** for the three months ended December 31, 2022[60](index=60&type=chunk)[62](index=62&type=chunk) Key Management Personnel Compensation (Three Months Ended Dec 31) | Category ($ thousands) | 2022 | 2021 | | :--- | :--- | | Salaries and Benefits | 291 | 267 | | Stock-based compensation | 237 | 1,096 | | **Total** | **528** | **1,363** | [Note 17: Subsequent event](index=24&type=section&id=Note%2017%3A%20Subsequent%20event) This note describes a significant subsequent event, the acquisition of Great Elm Healthcare, LLC, including its funding and pro forma financial impact - On January 3, 2023, the company acquired Great Elm Healthcare, LLC for a purchase price of **$80 million**[64](index=64&type=chunk) - The acquisition was funded with approximately **$73 million** in cash from the senior credit facility, **$5 million** in assumed debt, and **$2 million** (**431,996 shares**) in Quipt common stock[64](index=64&type=chunk) - Pro forma results for the three months starting October 1, 2022, indicate Great Elm would have generated approximately **$15 million** in revenue and a net loss of **$500,000**[65](index=65&type=chunk)

Financial Data and Key Metrics Changes - Quipt Home Medical reported revenue of $40.1 million for Q4 2022, a 37.8% increase from $29.1 million in Q4 2021, and total revenue for fiscal year 2022 reached $139.9 million, up 36.7% from $102.4 million in fiscal year 2021 [14][21][22] - Adjusted EBITDA for Q4 2022 was $8.4 million with a margin of 21%, compared to $5.5 million in Q4 2021, representing a 54% increase [22] - The company achieved an adjusted EBITDA of $29.2 million for fiscal year 2022, with a margin of 20.9%, up from $21.4 million in fiscal year 2021 [21][24] Business Line Data and Key Metrics Changes - Respiratory resupply setups and deliveries increased to 231,495 for the year ended September 30, 2022, a 46.4% increase from 158,072 in the previous year [20] - The customer base grew by 23% year-over-year, reaching 173,203 unique patients served in fiscal year 2022 [20] Market Data and Key Metrics Changes - The company operates in a favorable regulatory environment, with Medicare fee schedule adjustments resulting in a CPI increase for DME providers of 6.4% to 9.1% for calendar 2023 [10][12] - The cancellation of the 2021 competitive bidding program for 13 product categories has provided a clear margin outlook across the product mix [12] Company Strategy and Development Direction - Quipt aims to transition from a regional to a national at-home respiratory care provider, focusing on expanding its sales team and enhancing patient accessibility [7][8] - The company plans to continue its growth strategy through strategic acquisitions, with five acquisitions completed in 2022, adding over 45,000 active patients and $35 million in revenue [27][40] - The company is focused on increasing market share through organic growth initiatives, technology deployment, and strategic acquisitions [38][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting the guidance of $180 million in revenue by the end of calendar year 2023, despite some uncertainties regarding acquisition timing [53][54] - The company anticipates organic growth to return to historical rates of 7% to 10% in 2023, driven by increased device availability and CPI adjustments [76][77] Other Important Information - Quipt has a strong balance sheet with $110 million in senior secured credit facilities, providing financial flexibility for future growth [28][43] - The company has surpassed 200,000 active patients and operates 94 locations across 19 states [18][34] Q&A Session Summary Question: Outlook for growth across various products - Management expects the product mix to remain steady, with 80% from respiratory products and 20% from other DME supplies [46] Question: Integration of acquisitions - The integration of recent acquisitions is winding down, with expectations of margin improvement as full integration is completed [48] Question: Sales team growth - The company plans to increase its sales team by 50% in 2023, focusing on ramping up new hires [49] Question: Guidance for top line revenue - Management is confident in meeting the $180 million guidance but acknowledges the unpredictability of acquisition timing [53][54] Question: Pricing of deals in the pipeline - The current environment is expected to favor buyers, with lower multiples observed compared to previous months [56][58] Question: Status of sleep device backlog - Supply levels are approaching pre-pandemic levels, and the backlog is not being monitored as closely due to improved supply chain conditions [61][62] Question: Organic growth for the quarter - Organic growth was flat from Q3 to Q4, but management expects a reversal of the previous casketing effect leading to increased growth in 2023 [65][75] Question: Wage inflation and labor market - Wage inflation has been steady, but improvements in talent pools have led to greater efficiencies [66] Question: Run rate guidance for 2023 - The company is not providing run rate guidance for 2023 at this time but may do so later in the year [71]

Exhibit 99.1 QUIPT HOME MEDICAL REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS POSTING POSITIVE NET INCOME, REVENUE GROWTH OF 37% AND ADJUSTED EBITDA GROWTH OF 37% POSTS STRONG ADJUSTED EBITDA MARGIN OF 20.9% FOR FISCAL YEAR 2022 Cincinnati, Ohio – December 21, 2022 – Quipt Home Medical Corp. (the "Company") (NASDAQ:QIPT; TSXV:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2022 financial re ...

Quipt Home Medical Corp. (NASDAQ:QIPT) Q3 2022 Results Conference Call August 16, 2022 10:00 AM ET Company Participants Greg Crawford - Chairman and Chief Executive Officer Hardik Mehta - Chief Financial Officer Thomas Roehrig - Executive Vice President of Finance Conference Call Participants Doug Cooper - Beacon Securities Sepehr Manochehry - Eight Capital Rahul Sarugaser - Raymond James Paul Stewardson - iA Capital Markets Justin Keywood - Stifel Stefan Quenneville - Echelon Capital Markets Operator Thank ...